What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
Yawning is an unusual side effect of antidepressant medications. Here, read the case of a patient who developed yawning with every antidepressant she was prescribed, resulting in discontinuation of the medication.
Psyllium is often used to reduce constipation, but could it make a coadministered medication less effective? This report describes an unexpected interaction.
In this brief report, the authors evaluate the effects of a possible association between different bupropion formulations and treatment-emergent insomnia in veterans with major depressive disorder prescribed bupropion based on provider discretion.
Here, read about a 29-year-old woman who presented to our inpatient psychiatric facility for manic-like symptoms including pressured speech, flight of ideas, sexual preoccupations, and self-reported euphoria.
This report presents a case in which a visually impaired patient describes the development of visual hallucinations after 2 oral administrations of thiocolchicoside.
Serotonin syndrome appears in different gradations of severity, affecting recognition and reporting. Read this case report to find out more about this condition.
New-onset enuresis may be an underreported side effect of clozapine. The authors of this case report recommend directly questioning patients about clozapine-induced enuresis rather than vaguely inquiring about side effects.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT